AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report)'s share price was up 7.2% on Thursday . The stock traded as high as $3.14 and last traded at $3.14. Approximately 570,329 shares changed hands during trading, a decline of 68% from the average daily volume of 1,788,647 shares. The stock had previously closed at $2.93.
Wall Street Analyst Weigh In
ABCL has been the topic of several recent analyst reports. Stifel Nicolaus reiterated a "buy" rating and issued a $12.00 price target (down previously from $14.00) on shares of AbCellera Biologics in a research note on Tuesday, November 5th. Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a research note on Tuesday, November 5th.
Check Out Our Latest Stock Analysis on AbCellera Biologics
AbCellera Biologics Stock Up 3.4 %
The firm has a market capitalization of $894.96 million, a price-to-earnings ratio of -4.97 and a beta of 0.41. The stock has a 50 day moving average of $2.85 and a 200 day moving average of $2.79.
AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. The firm had revenue of $6.51 million during the quarter, compared to the consensus estimate of $8.95 million. During the same quarter last year, the firm posted ($0.10) earnings per share. Analysts predict that AbCellera Biologics Inc. will post -0.59 earnings per share for the current year.
Institutional Investors Weigh In On AbCellera Biologics
A number of institutional investors have recently modified their holdings of ABCL. Walleye Capital LLC acquired a new position in AbCellera Biologics in the third quarter valued at approximately $668,000. Renaissance Technologies LLC boosted its position in AbCellera Biologics by 16.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,728,603 shares of the company's stock valued at $5,117,000 after purchasing an additional 239,000 shares during the period. GSA Capital Partners LLP grew its stake in AbCellera Biologics by 991.3% during the 3rd quarter. GSA Capital Partners LLP now owns 241,866 shares of the company's stock worth $629,000 after buying an additional 219,703 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in AbCellera Biologics in the second quarter worth $923,000. Finally, Headlands Technologies LLC acquired a new stake in AbCellera Biologics in the second quarter worth $146,000. Institutional investors own 61.42% of the company's stock.
About AbCellera Biologics
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Featured Stories
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
